Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma
Prof Sandip Patel speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the DART study, which examined the administration of ipilimumab plus nivolumab to achieve dual checkpoint inhibition in a cohort of patients with rare neuroendocrine tumours.
Prof Patel reports that these patients experienced a 44 percent reduction in tumour size, compared with patients with lower, intermediate disease - who experienced a 0 percent rate of shrinkage.
Although it is unclear why patients with high-grade neuroendocrine carcinoma benefitted from this study, Prof Patel points out that it may be attributed to a mutational burden; in which specimens are being assessed to understand the underlying tumour biology.
He also believes in the next three years, oncologists will be able to determine which rare tumour types display a sensitivity to immune checkpoint blockade - which may include high-grade neuroendocrine carcinoma.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
-
Category
No comments found